Abstract
Purpose of Review: With the growing prevalence of heart failure, there is a particular need to develop new pharmacologic treatments that can improve outcomes. While there are several approved therapies for heart failure with reduced ejection fraction, there is currently no approved agent for those with preserved ejection fraction. The current review aimed to explore the utility of alternate endpoints to mortality and hospitalization. Recent Findings: There is increased interest in the use of alternative endpoints such as functional status and quality of life for heart failure drug development to focus on patients feeling better in addition to improving outcomes. This should ideally be measured using objective as well as subjective parameters. Summary: While mortality and hospitalization remain important endpoints for clinical trials in heart failure, other more patient-centered outcomes are attractive alternatives yet how to best incorporate these in a trial setting remains to be elucidated.
| Original language | English |
|---|---|
| Pages (from-to) | 210-216 |
| Number of pages | 7 |
| Journal | Current Heart Failure Reports |
| Volume | 14 |
| Issue number | 4 |
| DOIs | |
| State | Published - 1 Aug 2017 |
| Externally published | Yes |
Keywords
- Clinical trial
- Endpoint
- Functional status
- Heart failure
- Quality of life